...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of interferon and cytokine research: The official journal of the International Society for Interferon and Cytokine Research >Acute-phase proteins and hematologic values in ovine lentivirus-infected lambs treated with recombinant ovine IFN-tau.
【24h】

Acute-phase proteins and hematologic values in ovine lentivirus-infected lambs treated with recombinant ovine IFN-tau.

机译：重组绵羊IFN-tau处理的绵羊慢病毒感染的羔羊的急性期蛋白和血液学价值。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To evaluate changes in complete blood cell (CBC) counts, haptoglobin and fibrinogen in ovine lentivirus (OvLV)-infected lambs treated with recombinant ovine interferon-tau (rOVIFN-tau), 24 lambs were allocated to one of four groups (n = 6 per group): (1) virus + rOvIFN-tau, VI, (2) virus + placebo, VP, (3) no virus + rOVIFN-tau, NVI, and (4) no virus + placebo, NVP. Three lambs in each group were treated once a day for 12 weeks, and the remaining 3 lambs were treated for 33 weeks. Blood was collected at days 0, 7, and 10 and at weeks 2-10, 12, 32, and 33 to determine CBC counts, as well as haptoglobin and fibrinogen levels. Hematologic values remained within normal limits in all groups. However, hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and packed cell volume (PCV) values decreased (p < 0.05) in the two rOvIFN-tau-treated groups (VI and NVI) compared with the placebo-treated (VP and NVP) groups. Both rOvIFN-upsilon and OvLV had a mild negative effect on neutrophil numbers. Although Hb, MCV, MCHC, PCV, and neutrophil values declined in the rOvIFN-tau-treated lambs compared with the placebo-treated lambs, these values remained within the reference range for sheep. Experimental lambs did not show adverse clinical signs associated with OvLV infection or as a result of rOvIFN-tau treatment. The lack of significant side effects of high-dose rOvIFN-tau in sheep and previous reports of broad-spectrum and cross-species antiviral activity suggest that rOvIFN-tau warrants further investigation as an antiviral therapeutic agent.
机译：为了评估用重组绵羊干扰素-tau（rOVIFN-tau）处理的绵羊慢病毒（OvLV）感染的羔羊的全血细胞（CBC）计数，触珠蛋白和纤维蛋白原的变化，将24只羔羊分配到四组之一（n = 6）每组）：（1）病毒+ rOvIFN-tau，VI，（2）病毒+安慰剂，VP，（3）无病毒+ rOVIFN-tau，NVI，和（4）无病毒+安慰剂，NVP。每组三只小羊每天接受一次治疗12周，其余三只小羊则接受33周治疗。在第0、7和10天以及第2-10、12、32和33周收集血液，以确定CBC计数以及触珠蛋白和纤维蛋白原水平。所有组的血液学值均保持在正常范围内。但是，在两个rOvIFN-tau治疗组（VI和NVI）中，血红蛋白（Hb），平均红细胞体积（MCV），平均红细胞血红蛋白浓度（MCHC）和包装细胞体积（PCV）值降低（p <0.05）。与安慰剂治疗（VP和NVP）组相比。 rOvIFN-upsilon和OvLV均对中性粒细胞数量有轻微的负面影响。尽管与安慰剂处理的羔羊相比，rOvIFN-tau处理的羔羊的Hb，MCV，MCHC，PCV和中性粒细胞值下降，但这些值仍在绵羊的参考范围内。实验羔羊没有显示出与OvLV感染或rOvIFN-tau治疗相关的不良临床体征。高剂量rOvIFN-τ在绵羊中缺乏显着的副作用以及先前关于广谱和跨物种抗病毒活性的报道表明，rOvIFN-τ作为抗病毒治疗剂值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号